NPS down 3% after Reuters says Shire preparing for bids Shares of NPS Pharmaceuticals (NPSP) are down 3% to $33.57 after Reuters reported that Shire (SHPG) has hired Citi to prepare for takeover offers. Press reports have speculated that NPS is a buyout target of Shire.
Shire's NDA for lifitegrast for dry eye resubmssion acknowledged by FDA Shire announced that the FDA has acknowledged receipt of the resubmission of the New Drug Application for lifitegrast for the treatment of signs and symptoms of dry eye disease in adults. Shire resubmitted the NDA in response to the complete response letter received from the FDA on October 16, 2015 that requested an additional clinical study and more information related to product quality. The FDA determined that the submission is a complete response and has assigned a 6-month review period for the NDA and a Prescription Drug User Fee Act goal date of July 22.